Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.
Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ACRS declined 5.77%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT.
A live and archived webcast of the presentation will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
When is Aclaris Therapeutics (ACRS) presenting at the H.C. Wainwright Conference?
How can investors access the Aclaris Therapeutics (ACRS) conference presentation?
How long will the Aclaris Therapeutics (ACRS) presentation recording be available?
What is the focus of Aclaris Therapeutics (ACRS) as a company?
